A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...

The provision of renewable energy solutions to GSK demonstrates a long-term commitment ... is expected to generate around 52 per cent of the factory’s energy demand. However, some locals have ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024. GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

The provision of renewable energy solutions to GSK demonstrates a long-term commitment to the site and the region." The solar farm is expected to generate around 52 per cent of the factory’s ...